These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 9649960

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.
    Presse Med; 2002 Nov 09; 31(36):1714-20. PubMed ID: 12467154
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Calcium antagonists and the diabetic hypertensive patient.
    Parving HH, Rossing P.
    Am J Kidney Dis; 1993 Jun 09; 21(6 Suppl 3):47-52. PubMed ID: 8503435
    [Abstract] [Full Text] [Related]

  • 8. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
    Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH.
    Diabetes Care; 2000 Dec 09; 23(12):1725-30. PubMed ID: 11128341
    [Abstract] [Full Text] [Related]

  • 9. Approach to the treatment of diabetic nephropathy.
    Burke JM.
    Pharm Pract Manag Q; 1997 Jul 09; 17(2):26-35. PubMed ID: 10168175
    [Abstract] [Full Text] [Related]

  • 10. Renal protection and antihypertensive drugs: current status.
    Salvetti A, Mattei P, Sudano I.
    Drugs; 1999 May 09; 57(5):665-93. PubMed ID: 10353294
    [Abstract] [Full Text] [Related]

  • 11. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 May 09; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 12. Renal protection in diabetes--an emerging role for calcium antagonists.
    Parving HH, Tarnow L, Rossing P.
    Cardiology; 1997 May 09; 88 Suppl 3():56-62. PubMed ID: 9397296
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB, Britton ML.
    Pharmacotherapy; 2005 Nov 09; 25(11):1602-20. PubMed ID: 16232022
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease.
    Ritz E, Orth SR, Strzelczyk P.
    J Hypertens Suppl; 1997 Mar 09; 15(2):S21-6. PubMed ID: 9218194
    [Abstract] [Full Text] [Related]

  • 16. [Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2].
    Zidek W.
    MMW Fortschr Med; 2004 Oct 14; 146(42):51-2. PubMed ID: 15536706
    [No Abstract] [Full Text] [Related]

  • 17. Differences in renal outcomes with ACE inhibitors in type 1 and type 2 diabetic patients: possible explanations.
    Jerums G.
    Miner Electrolyte Metab; 1998 Oct 14; 24(6):423-37. PubMed ID: 9930382
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases.
    Mimran A, Ribstein J.
    Am J Hypertens; 1994 Sep 14; 7(9 Pt 2):73S-81S. PubMed ID: 7818839
    [Abstract] [Full Text] [Related]

  • 19. Early detection of endothelial dysfunction and early therapeutic correction effectively restore renal function in type 2 diabetic nephropathy.
    Futrakul N, Butthep P.
    Ren Fail; 2005 Sep 14; 27(4):493-4. PubMed ID: 16060141
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.